...
首页> 外文期刊>Addiction >A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths.
【24h】

A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths.

机译:验尸毒理学研究中对死亡原因的重要评论:对34例丁丙诺啡相关的死亡和35例与美沙酮相关的死亡进行分析。

获取原文
获取原文并翻译 | 示例

摘要

AIMS: To assess the trends in the number, mortality and the nature of forensic cases involving toxicological detection of buprenorphine or methadone among toxicological investigations performed in Paris from June 1997 to June 2002. DESIGN: Retrospective, 5 year study with review of premortem data, autopsy, police reports, hospital data, and post-mortem toxicological analyses. SETTING AND PARTICIPANTS: 34 forensic cases of buprenorphine and 35 forensic cases of methadone detection among 1600 toxicological investigations performed at the Laboratory of Toxicology in the Medical Examiner's Office in Paris. MEASUREMENTS AND RESULTS: Therapeutic, toxic or lethal drug concentrations were defined based upon the results of blood analyses and the published literature. Drug concentrations were cross-referenced with other available ante- and post-mortem data. Subsequently, we classified a 'clear responsibility', 'possible responsibility' or 'not causative' role for buprenorphine or methadone in the death process, or 'no explanation of death'. Buprenorphine and methadone can be regarded as being directly implicated in, respectively, four of 34 death cases (12%) and three of 35 death cases (9%), and their participation in the lethal process is strongly plausible in eight (buprenorphine) and 11 (methadone) additional deaths. CONCLUSIONS: Analysis of causes of death reveals the difficulties in determining the role of substitution drugs in the death process, as many other factors may be involved, including circumstances surrounding death, past history, differential selection of subjects into either substitution modality and concomitant intake of other drugs (especially benzodiazepines and neuroleptics). The potential for synergistic or additive actions by other isolated molecules-particularly opioids, benzodiazepines, other psychotropes and alcohol-must be also considered.
机译:目的:从1997年6月至2002年6月在巴黎进行的毒理学调查中,评估涉及毒理学检测丁丙诺啡或美沙酮的法医案件的数量,死亡率和性质的趋势。设计:回顾性五年研究,回顾了死前数据,尸检,警察报告,医院数据和验尸毒理学分析。地点和参与者:在巴黎体检办公室毒理学实验室进行的1600项毒理学调查中,有34例丁丙诺啡法医病例和35例美沙酮法医检测病例。测量和结果:根据血液分析结果和已发表的文献确定治疗,毒性或致死性药物的浓度。将药物浓度与其他可用的事前和事后数据进行交叉参考。随后,我们将丁丙诺啡或美沙酮在死亡过程中的作用分为“明确责任”,“可能的责任”或“非致病性”,或“没有死亡原因”。丁丙诺啡和美沙酮分别被认为直接涉及34例死亡病例中的4例(12%)和35例死亡病例中的3例(9%),并且它们在致命过程中的参与在8例(丁丙诺啡)中是很可能的。另有11人(美沙酮)死亡。结论:死亡原因分析揭示了确定替代药物在死亡过程中的作用的困难,因为可能涉及许多其他因素,包括死亡情况,既往史,将受试者差异选择为替代方式和伴随摄入其他药物(尤其是苯二氮卓类和抗精神病药)。还必须考虑其他孤立分子(尤其是阿片类药物,苯二氮卓类,其他精神药物和酒精)产生协同或加成作用的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号